Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21

Cancer Letters

Volumn 298, Issue 1, 2010, Pages 16-25

  Wu, Hsien Ming ^a,b,c   Schally, Andrew V ^d   Cheng, Jung Chien ^a   Zarandi, Marta ^d   Varga, Jozsef ^d   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Endometrial cancer; Growth hormone releasing hormone; P21; P53; PKC

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CASPASE 3; GROWTH HORMONE RELEASING FACTOR; JMR 132; PROTEIN KINASE C DELTA; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BISINDOLYLMALEIMIDE I; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GHRH(1-29)NH2, PHACTYR(1)-ARG(2)-P(H)E(4-CL)(6)-ALA(8)-TYR(ME)(10)-HIS(11)-ABU(15)-HIS(20)-NLE(27)-ARG(28)-HLCR(29)-; INDOLE DERIVATIVE; ISOPROTEIN; MALEIMIDE DERIVATIVE; MESSENGER RNA; SERMORELIN; TP53 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENDOMETRIAL NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GROWTH HORMONE-RELEASING HORMONE; HUMANS; INDOLES; MALEIMIDES; PROTEIN ISOFORMS; PROTEIN KINASE C-DELTA; RNA, MESSENGER; RNA, SMALL INTERFERING; SERMORELIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956905082     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.022     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA-A Cancer Journal for Clinicians 2008, 58:71-96.
2. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I. Endometrial cancer. Lancet 2005, 366:491-505.
3. Barabutis N., Schally A.V. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. British Journal of Cancer 2008, 98:1790-1796.
4. Schally A.V., Varga J.L., Engel J.B. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Practice 2008, 4:33-43.
5. Schally A.V., Varga J.L. Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends in Endocrinology and Metabolism 1999, 10:383-391.
6. Engel J.B., Keller G., Schally A.V., Toller G.L., Groot K., Havt A., Armatis P., Zarandi M., Varga J.L., Halmos G. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. The Journal of Clinical Endocrinology and Metabolism 2005, 90:3614-3621.
7. Zhao L., Yano T., Osuga Y., Nakagawa S., Oishi H., Wada-Hiraike O., Tang X., Yano N., Kugu K., Schally A.V., Taketani Y. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. International Journal of Oncology 2008, 32:593-601.
8. Rekasi Z., Czompoly T., Schally A.V., Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10561-10566.
9. Toller G.L., Horvath J.E., Schally A.V., Halmos G., Varga J.L., Groot K., Chism D., Zarandi M. Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:15160-15165.
10. Csernus V.J., Schally A.V., Kiaris H., Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:3098-3103.
11. Schally A.V., Varga J.L. Antagonists of growth hormone-releasing hormone in oncology. Combinatorial Chemistry & High Throughput Screening 2006, 9:163-170.
12. Fujii T., Garcia-Bermejo M.L., Bernabo J.L., Caamano J., Ohba M., Kuroki T., Li L., Yuspa S.H., Kazanietz M.G. Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. The Journal of Biological Chemistry 2000, 275:7574-7582.
13. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71:587-597.
14. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. P21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704.
15. Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi K. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 1985, 37:1103-1111.
16. Mo B., Vendrov A.E., Palomino W.A., DuPont B.R., Apparao K.B., Lessey B.A. ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biology of Reproduction 2006, 75:387-394.
17. Buchholz S., Schally A.V., Engel J.B., Hohla F., Heinrich E., Koester F., Varga J.L., Halmos G. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:1943-1946.
18. Halmos G., Schally A.V., Varga J.L., Plonowski A., Rekasi Z., Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10555-10560.
19. Kiaris H., Schally A.V., Busto R., Halmos G., Artavanis-Tsakonas S., Varga J.L. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:196-200.
20. Kiaris H., Chatzistamou I., Schally A.V., Halmos G., Varga J.L., Koutselini H., Kalofoutis A. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:9512-9517.
21. Barabutis N., Tsellou E., Schally A.V., Kouloheri S., Kalofoutis A., Kiaris H. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:5575-5579.
22. Pollak M.N., Polychronakos C., Richard M. Insulin like growth factor I: a potent mitogen for human osteogenic sarcoma. Journal of the National Cancer Institute 1990, 82:301-305.
23. Pollak M., Sem A.W., Richard M., Tetenes E., Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Journal of the National Cancer Institute 1992, 84:966-971.
24. 2 as a GRF antagonist on membranes. Endocrinology 1985, 117:1759-1764.
25. Stangelberger A., Schally A.V., Zarandi M., Heinrich E., Groot K., Havt A., Kanashiro C.A., Varga J.L., Halmos G. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. The Prostate 2007, 67:1339-1353.
26. Volakaki A.A., Lafkas D., Kassi E., Schally A.V., Papavassiliou A.G., Kiaris H. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132. Journal of Molecular Endocrinology 2008, 41:389-392.
27. Hohla F., Schally A.V., Szepeshazi K., Varga J.L., Buchholz S., Koster F., Heinrich E., Halmos G., Rick F.G., Kannadka C., Datz C., Kanashiro C.A. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:14513-14518.
28. Song J.S., Swann P.G., Szallasi Z., Blank U., Blumberg P.M., Rivera J. Tyrosine phosphorylation-dependent and -independent associations of protein kinase C-delta with Src family kinases in the RBL-2H3 mast cell line: regulation of Src family kinase activity by protein kinase C-delta. Oncogene 1998, 16:3357-3368.
29. Newton A.C. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chemical Reviews 2001, 101:2353-2364.
30. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene 2003, 22:9030-9040.
31. Vazquez A., Bond E.E., Levine A.J., Bond G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature Reviews 2008, 7:979-987.
32. Meulmeester E., Jochemsen A.G. p53: a guide to apoptosis. Current Cancer Drug Targets 2008, 8:87-97.
33. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991, 352:345-347.
34. Fotedar R., Brickner H., Saadatmandi N., Rousselle T., Diederich L., Munshi A., Jung B., Reed J.C., Fotedar A. Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 1999, 18:3652-3658.
35. Shibata M.A., Yoshidome K., Shibata E., Jorcyk C.L., Green J.E. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Therapy 2001, 8:23-35.
36. Kondo S., Barna B.P., Kondo Y., Tanaka Y., Casey G., Liu J., Morimura T., Kaakaji R., Peterson J.W., Werbel B., Barnett G.H. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996, 13:1279-1285.
37. Lincet H., Poulain L., Remy J.S., Deslandes E., Duigou F., Gauduchon P., Staedel C. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Letters 2000, 161:17-26.
38. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Research 1994, 54:1169-1174.
39. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Molecular Cancer Therapeutics 2002, 1:639-649.
40. Liu S., Bishop W.R., Liu M. Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resistance Updates 2003, 6:183-195.